Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 25/100

ADMA SHAREHOLDER ALERT: ADMA Biologics, Inc. is Under Investigation for Securities Fraud after Auditor Resignation and 20% Stock Drop; Investors are Urged to Contact BFA Law (Nasdaq:ADMA)

Key Takeaway: ADMA Biologics, Inc. is under investigation for potential securities fraud following the unexpected resignation of its independent auditor, CohnReznick LLP. This development led to a significant decrease in the stock price, plunging more than 20% on October 10, 2024. Investors are being urged to seek further information and consider legal options regarding their investments. The situation raises significant concerns about the company's financial transparency and stability.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics experienced a sudden resignation of its independent auditor, which raises concerns about the company's financial reliability.
  • The stock price of ADMA Biologics fell over 20%, indicating a significant loss of investor confidence.
  • An investigation for potential securities fraud has been announced, exposing further risks for investors.
  • The announcement of legal options for shareholders suggests potential financial damage.

Full Press Release Details

NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

What triggered the stock drop for ADMA Biologics?

ADMA Biologics’s stock dropped after the unexpected resignation of auditor CohnReznick LLP.

How much did ADMA Biologics's stock decline?

On October 10, 2024, ADMA Biologics's stock fell by over 20%.

What services does Bleichmar Fonti & Auld LLP provide?

Bleichmar Fonti & Auld LLP represents plaintiffs in securities class actions.

Is there a cost for shareholders to pursue legal action?

There are no costs for shareholders; representation is on a contingency fee basis.

Where can I find more information on the ADMA investigation?

You can visit https://www.bfalaw.com/cases-investigations/adma-biologics-inc.

Last updated: Oct 13, 2024